Concert Pharmaceuticals, Inc. (CNCE)

conpharmaConcert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that focuses on developing and manufacturing novel medicines by applying the company’s proprietary Deuterated Chemical Entity (DCE) Platform to compounds that have well-characterized pharmacological activity. This type of approach may enable less costly and more efficient drug discovery and clinical development compared to conventional small molecule drug research and development.

With the application of Concert’s extensive knowledge of deuterium chemistry, the company is focusing on the discovery and development of novel small molecule drugs. Their approach begins with systematically identifying approved drugs, advanced clinical candidates, or compounds that have the potential for improvement through deuterium substitution.

Unlike traditional drug discovery methods that have high failure rates, the company’s approach allows for better metabolic properties or better pharmacokinetics, thus enhancing clinical safety, efficacy, and tolerability for improved metabolic profile, bioavailability, and half-life. The company prioritizes candidate compounds according to medical needs, competitive and patent landscapes, commercial opportunity, and strategic fit.

Concert Pharmaceuticals, Inc. has executed on this particular approach in order to become a clinical stage biotechnology company. The company is developing a robust product candidate pipeline in various therapeutic areas. The company’s product candidates include CTP-499 for diabetic nephropathy, CTP-354 for spasticity associated with SCI and MS, AVP-786 for neurologic and psychiatric disorders, CTP-730 for inflammatory diseases, JZP-386 for narcolepsy, C-10068 for pain and seizures, and Deuterated Ivacaftor for CF and COPD.

Concert Pharmaceuticals, Inc. is traded in the OTC markets under the stock symbol CNCE. The company has developed the DCE Platform that consists of proprietary knowledge, information, and techniques that they have developed over the past 7 years. The company has a significant experience in pharmaceutical research and development and deuterium chemistry to product candidates that are optimally deuterated.


Yahoo! Finance: CNCE News

Latest Financial News for CNCE

Concert Pharmaceuticals Announces Initiation of New Open Label Trial to Evaluate Once-Daily vs. Twice-Daily Dosing of CTP-543 in Patients with Alopecia Areata

Concert Pharmaceuticals, Inc. (CNCE) today announced that it has initiated a second open label clinical trial to evaluate once-daily compared to twice-daily oral dosing of CTP-543 in patients with alopecia areata. Patients in the trial will be randomized to receive either 12 mg twice-daily or 24 mg once-daily of CTP-543 over a 24 week treatment period. This new dose regimen trial is designed to complement the first open label trial initiated by Concert in March 2019, which is ongoing in patients randomized to receive either 8 mg twice-daily or 16 mg once-daily of CTP-543 over a 24 week treatment period.

Concert Pharmaceuticals to Present at Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. today announced that it will participate at the following upcoming investor conferences:

Why Concert Pharmaceuticals, Inc.'s (NASDAQ:CNCE) CEO Pay Matters To You

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Roger Tung has been the CEO of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) since 2006. Thi...

Concert Pharmaceuticals, Inc. (CNCE) Q1 2019 Earnings Call Transcript

CNCE earnings call for the period ending March 31, 2019.